Avidity Biosciences, Inc. (RNA)

71.54 -0.04 (-0.06%) USD  |  NASDAQ  |  Dec 04, 16:00
71.53 -0.01 (-0.01%) After-Hours: 20:00
More

Avidity Biosciences Debt to Equity Ratio: 0.0265 for Sept. 30, 2025

Debt to Equity Ratio Chart

View Debt to Equity Ratio for RNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Debt to Equity Ratio Definition

View Debt to Equity Ratio Definition
Start Trial

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Novartis AG 0.7224
Dyne Therapeutics, Inc. 0.1741
EXACT Sciences Corp. 1.014
Eli Lilly & Co. 1.786
Intellia Therapeutics, Inc. 0.1309

Debt to Equity Ratio Related Metrics

Total Assets (Quarterly) 2.134B
Total Liabilities (Quarterly) 247.94M
Shareholders Equity (Quarterly) 1.886B
Current Ratio 11.57
Net Debt Paydown Yield -0.13%